Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Ocugen ( (OCGN) ) is now available.
On January 20, 2026, Ocugen, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc. for an underwritten public offering of 15 million shares of its common stock at $1.50 per share, raising gross proceeds of $22.5 million and an expected approximately $20.8 million in net proceeds after fees and expenses. The offering, led by RTW Investments with participation from new and existing investors and Oppenheimer acting as sole book-running manager, was expected to close on or about January 22, 2026, with Ocugen planning to use the funds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses, bolstering its financial resources to advance its gene therapy programs.
The most recent analyst rating on (OCGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
The score is held back primarily by weak financial performance (losses, high leverage, and strained cash metrics). Offsetting this are solid recent technical strength (despite overbought signals) and a more positive outlook from clinical/program progress, financing runway extension, and supportive new trial data.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Ocugen, Inc. is a biotechnology company focused on gene therapies for blindness diseases, leveraging a modifier gene therapy platform that takes a gene-agnostic approach to treating complex retinal conditions. Its development pipeline targets inherited retinal diseases and other blindness-causing disorders affecting large patient populations worldwide, including retinitis pigmentosa, Stargardt disease and geographic atrophy associated with late-stage dry age-related macular degeneration.
Average Trading Volume: 4,192,305
Technical Sentiment Signal: Buy
Current Market Cap: $527.8M
For a thorough assessment of OCGN stock, go to TipRanks’ Stock Analysis page.